Optimising Type 2 Diabetes Outcomes through Dapagliflozin and Sitagliptin FDC: A Gluco-Cardio-Renal Perspective

Type 2 Diabetes (T2D) is a major public health challenge, with India ranking second globally in prevalence. [1] The coexistence of diabetes, hypertension, and dyslipidemia accelerates atherosclerosis and endothelial dysfunction, leading to microvascular and macrovascular complications that drive cardiovascular diseases (CVDs). The key challenge for clinicians is identifying a comprehensive therapeutic option that can safely and effectively achieve glucose control along with cardiovascular and renal protection.[2]

Rationale for Considering Dapagliflozin and Sitagliptin-Based FDC Therapies – Targeting the Gluco-Cardio-Renal Perspective

An ideal glucose-lowering combination should have complementary mechanisms that address multiple pathophysiologic pathways across all disease stages, remain well tolerated, and avoid added risks of hypoglycemia or weight gain. It should also offer patient convenience through single-pill, once-daily dosing. [3] The SGLT2 inhibitor, Dapagliflozin, promotes osmotic diuresis and natriuresis, reducing preload and afterload while improving myocardial metabolism and hemodynamic stability. [4] The DPP-4 inhibitor, Sitagliptin, enhances incretin activity (GLP-1 – Glucagon-Like Peptide-1, GIP – Glucose-Dependent Insulinotropic Polypeptide), reducing postprandial glucose, preserving β-cell function, and remaining weight-neutral, providing durable glucose-lowering benefits. [5] Beyond glucose-lowering, weight reduction, blood pressure-lowering, and cardio-renal protection, dapagliflozin allows complete gluco-cardio-renal triad benefits relevant for Indian patients with T2D. [6] The dapagliflozin and sitagliptin FDC targets six of the eight components of the ominous octet, addressing key pathophysiological defects in T2DM [7] and associated oxidative stress; as an FDC, they further reduce pill burden, improve tolerability, and cost-effectiveness with effective PPG control. [8]

Dapagliflozin & Sitagliptin FDC: A Synergistic Clinical Evidence on Cardio-Renal & Metabolic Outcomes

Cardiovascular (CV) Benefit: CV burden remains the leading cause of disability and premature death in diabetes, with people with T2D facing a 1.5–2 times higher CVD risk than non-diabetics.[8] In the DECLARE–TIMI 58 trial (n=17,160, median follow-up 4.2 years), dapagliflozin significantly reduced cardiovascular death or hospitalization for heart failure by 17% (HR 0.83), driven primarily by a 27% reduction in heart failure hospitalization (HR 0.73), while maintaining noninferiority for major adverse cardiovascular events (MACE). [9]

In patients with type 2 diabetes, sitagliptin showed no increase in cardiovascular risk and, in head-to-head comparisons, demonstrated a 100% lower rate of cardiovascular events compared with sulphonylureas (IRR 0.00; 95% CI, 0.00–0.31). [10] Both agents have proven CV safety, making them a suitable dual therapy for patients with cardiovascular risk, including HF. [5,6]

Renal Benefit: CKD affects up to 40% of people with diabetes, and the lifetime risk of CKD in T2D can reach 54%, making renal protection central to comprehensive diabetes care. [11] In the DAPA-CKD trial, dapagliflozin significantly reduced the risk of ≥50% eGFR decline, end-stage kidney disease, or renal death by 44% (HR = 0.56; p < 0.001) and lowered the risk of cardiovascular death or heart failure hospitalization by 29% (HR = 0.71; p = 0.009). [6]

Sitagliptin demonstrated renal protection by mitigating high-glucose–induced oxidative stress and inflammation in glomerular endothelial cells. In a 3-month clinical study of 84 patients with T2DM, sitagliptin reduced the albumin-creatinine ratio (ACR) by 20.9 mg/g (from 314.4 to 293.5 mg/g; p < 0.001) and improved eGFR by 3.5 mL/min/1.73 m² (from 73.4 to 76.9 mL/min/1.73 m²; p < 0.001). The reduction in ACR was more pronounced in macroalbuminuric patients (−30.3 vs −11.1; p = 0.02), indicating sitagliptin’s renoprotective potential and role in preventing diabetic kidney disease (DKD). [12]

Metabolic Benefit- An Indian Experience: In a real-world, multicentre study involving 328 Indian T2DM patients (mean age 51.1 years; 77.7% males), over 12 weeks the FDC of dapagliflozin and sitagliptin decreased HbA1c by 1.05% ( from 8.36 to 7.31; p < 0.0001), while FPG dropped by 23 mg/dL (165.5 to 142.5; p < 0.0001) and PPBG by 41 mg/dL (242.1 to 201.2; p < 0.0001). It also reduced LDL-C by 18 mg/dL (121.4 to 103.2; p < 0.0001), SBP by 14.6 mmHg (147.0 to 132.4; p<0.0001), and DBP by 7.8 mmHg (90.3 to 82.5; p<0.0001). Mean body weight also decreased by 2.2 kg (74.9 to 72.8; p<0.0001), reflecting added metabolic benefit. These reductions in HbA1c, FPG, and PPBG collectively suggest an overall improvement in average daily glucose (ADG), adding another dimension to the metabolic benefits observed. [13]

Guideline Recommendations on Dapagliflozin and Sitagliptin Consideration in T2DM

International and Indian Guidelines support early combination therapy to achieve faster, more durable glycemic and cardio-renal protective benefits in T2DM. (Table 1)

Table 1: Dapagliflozin and Sitagliptin in T2D — Guideline Considerations

Key Messages

• The gluco-cardio-renal continuum highlights that dysfunction in one organ fuels the others, necessitating therapies that simultaneously protect glucose, heart, and kidney. [1,2]
• Dapagliflozin offers good glycemic control, weight, and BP-lowering effects and enhances hemodynamic stability, myocardial efficiency, and slows eGFR decline and reduces major renal outcomes, while sitagliptin preserves β-cell function and incretin activity, offering durable, weight-neutral glucose control. [4,5]
• Dapagliflozin reduced all-cause mortality by 34%, CV deaths by 22%, and HF worsening by 9%;8 sitagliptin showed a neutral CV and HF risk profile, and improved ACR and eGFR (both p<0.001). [9, 11,12]
• Indian evidence has reaffirmed the efficacy of dapagliflozin and sitagliptin FDC, showing reductions in HbA1c by 1.05%, SBP by 14.6 mmHg, DBP by 7.8 mmHg, LDL-C by 18 mg/dL, and weight by 2.2 kg 13; clinical benefits aligning with ADA, RSSDI, and Indian Expert Consensus 2025, which advocate early combination therapy in T2D for comprehensive gluco-cardio-renal protection. [14, 15, 16]

Abbreviations: ACR – Albumin–Creatinine Ratio, ADA – American Diabetes Association, ASCVD – Atherosclerotic Cardiovascular Disease, BP – Blood Pressure, CKD – Chronic Kidney Disease, CVD – Cardiovascular Disease, CV – Cardiovascular, DAPA-ACT HF–TIMI 68 – Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure - Thrombolysis in Myocardial Infarction 68, DBP – Diastolic Blood Pressure, DKD – Diabetic Kidney Disease, DPP-4 – Dipeptidyl Peptidase-4, EF – Ejection Fraction, eGFR – Estimated Glomerular Filtration Rate, ESC – European Society of Cardiology, FDC – Fixed-Dose Combination, FPG – Fasting Plasma Glucose, GLP-1 – Glucagon-Like Peptide-1, GIP – Glucose-Dependent Insulinotropic Polypeptide, HbA1c – Glycated Hemoglobin, HF – Heart Failure, HFpEF – Heart Failure with Preserved Ejection Fraction, HFrEF – Heart Failure with Reduced Ejection Fraction, HR – Hazard Ratio, LDL-C – Low-Density Lipoprotein Cholesterol, IRR- Incidence Rate Ratio, MACE – Major Adverse Cardiovascular Events, PPBG – Postprandial Blood Glucose, RSSDI – Research Society for the Study of Diabetes in India, SBP – Systolic Blood Pressure, SGLT2 – Sodium–Glucose Cotransporter-2, SIDAXA –Study to Assess Safety, Clinical Utilization, and Effectiveness of Sitagliptin & Dapagliflozin Combination Therapy in the Treatment of Type 2 Diabetes for Extra Glycaemic Advantages, T2D / T2DM – Type 2 Diabetes Mellitus